Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline

Bayer AG/Algeta ASA have halted early a Phase III trial evaluating their first-in-class targeted radioactive drug Alpharadin (radium 223-chloride) for the treatment of symptomatic bone metastases in advanced prostate cancer patients based on positive interim results.